Liberate Bio

Executive Summary

Liberate Bio is a private biotechnology company founded in 2021 and headquartered in San Diego, focused on overcoming the liver-centric delivery limitations of current genetic medicine technologies. The company's proprietary RAPTOR™ platform is designed to identify and develop lipid nanoparticle (LNP) formulations capable of delivering genetic payloads to historically inaccessible cell types, particularly within the bone marrow and immune system. By enabling in vivo reprogramming of these disease-driving cells, Liberate Bio aims to unlock new therapeutic modalities for a range of hematologic, immunologic, and genetic disorders. The company's approach addresses a critical bottleneck in the field: extrahepatic delivery of RNA and gene-editing therapies. At its current early stage, Liberate Bio is advancing its RAPTOR platform through preclinical studies and building partnerships to validate its delivery capabilities. The company has not yet disclosed a specific lead program or financing details but is positioned in a high-demand area of drug delivery. If successful, its technology could significantly expand the addressable market for genetic medicines beyond the liver. Near-term value drivers include preclinical proof-of-concept data, strategic collaborations with larger biopharma, and a likely Series B financing round to support IND-enabling studies.

Upcoming Catalysts (preview)

• H2 2026Preclinical proof-of-concept data for RAPTOR enabling delivery to bone marrow stem cells70% success
• 2027Strategic partnership with a major pharmaceutical company for LNP delivery of RNA therapeutics50% success
• 2026Series B financing round to advance lead programs and platform60% success